SpringWorks Therapeutics (SWTX) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Key value drivers and strategic overview

• Ogsiveo launched for desmoid tumors, exceeding expectations with rapid adoption and strong patient benefit.

• Patient pool for desmoid tumors is larger than initially estimated, with over 10,000 unique ICD-10 claims in nine months.

• Mirtametinib for NF1-PN has a February 28th PDUFA date, targeting a larger patient population.

• Three major launches planned in the next 12 months: US and EU launches for mirtametinib and EU launch for Ogsiveo.

• Focus remains on execution of current launches and maximizing value from existing pipeline.

Commercial performance and market dynamics

• Ogsiveo has become the systemic standard of care for desmoid tumors, with over 50% of systemic patients on the drug.

• 800 unique prescriptions in September, with strong month-over-month growth.

• Peak US sales opportunity for Ogsiveo is projected at over $1 billion, with growing confidence in this estimate.

• Blister pack introduction improved adherence and refill rates, with transition expected to complete by January.

• Seasonality impacts are expected but are diminishing as the patient base grows.

Clinical data and patient outcomes

• Long-term data shows continued benefit and improved outcomes for patients staying on Ogsiveo up to three years.

• Less than 10% discontinuation rate, with most adverse events occurring early and being manageable.

• Ovarian dysfunction is reversible and not a significant barrier to treatment.

• New data supports longer-term dosing and persistence, addressing concerns about therapy drop-off at one year.